Dyadic International Inc.
DYAIDyadic International Inc.’s revenue for fiscal 2025 (year ended December 2025) was $3.1 million, down 11.6% from fiscal 2024.
- Revenue
- −61.4%
- EPS
- n/m
- Free cash flow
- n/m
- Total debt
- +0.80%
Quarter to September 2026, against a year earlier
Follow DYAI
Alert me
Dyadic International Inc. (DYAI) EV/Sales
As of 13 November 2026, Dyadic International Inc. (DYAI) trades at a EV/Sales of 4.1×. Over the past ten years it has ranged from −18.5× (April 2016) to 197× (December 2015); the current reading is higher than 22% of that period. That is below the Biotechnology industry median of 8.6× and above the Healthcare sector median of 3.5×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 8.8× | (34.71%) |
| FY2024 | 13.5× | 0.95% |
| FY2023 | 13.3× | 47.34% |
| FY2022 | 9.0× | (79.41%) |
| FY2021 | 43.9× | (40.73%) |
| FY2020 | 74.1× | 17.90% |
| FY2019 | 62.9× | 633.31% |
| FY2018 | 8.6× | 3,309.23% |
| FY2017 | 0.3× | — |
| FY2016 | −8.3× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Sep 2026 | 5.6× | (36.05%) |
| Jun 2026 | 8.7× | 17.11% |
| Mar 2026 | 7.4× | (15.18%) |
| Dec 2025 | 8.8× | (17.26%) |
| 42 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| NEUP Neuphoria Therapeutics Inc. compare | −0.5× |
| ALGS Aligos Therapeutics, Inc. compare | −0.3× |
| ALLR Allarity Therapeutics, Inc. compare | n/m |
| NCEL NewcelX Ltd. compare | n/m |
| LSTA Lisata Therapeutics, Inc. compare | 0.3× |
| DYAI Dyadic International Inc. | 4.1× |
| QNTM Quantum Biopharma Ltd. compare | 4.2× |
| PLUR Pluri Inc. compare | 23.1× |
| MCRB Seres Therapeutics, Inc. compare | 46.7× |
| Biotechnology industry median | 8.6× |
| Healthcare sector median | 3.5× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)